These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comparison of Whole-Body DWI and 18F-FDG PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma. Chen J, Li C, Tian Y, Xiao Q, Deng M, Hu H, Wen B, He Y. AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755 [Abstract] [Full Text] [Related]
4. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed TL, Verma N, Hochhegger B. Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513 [Abstract] [Full Text] [Related]
5. Diagnostic value of WB-DWI versus 18F-FDG PET/CT for the detection of multiple myeloma. Zhang B, Zhang L, Bian B, Lin F, Zhu Z, Wang J. Indian J Cancer; 2023 Jul; 60(3):303-309. PubMed ID: 37787189 [Abstract] [Full Text] [Related]
7. Accuracy of whole-body diffusion-weighted MRI (WB-DWI/MRI) in diagnosis, staging and follow-up of gastric cancer, in comparison to CT: a pilot study. De Vuysere S, Vandecaveye V, De Bruecker Y, Carton S, Vermeiren K, Tollens T, De Keyzer F, Dresen RC. BMC Med Imaging; 2021 Feb 05; 21(1):18. PubMed ID: 33546626 [Abstract] [Full Text] [Related]
8. Diagnostic Value of Whole-Body DWI With Background Body Suppression Plus Calculation of Apparent Diffusion Coefficient at 3 T Versus 18F-FDG PET/CT for Detection of Bone Metastases. Sun W, Li M, Gu Y, Sun Z, Qiu Z, Zhou Y. AJR Am J Roentgenol; 2020 Feb 05; 214(2):446-454. PubMed ID: 31799866 [Abstract] [Full Text] [Related]
9. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Catalano OA, Daye D, Signore A, Iannace C, Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A, Salvatore M, Fuin N, Catana C, Mahmood U, Rosen BR. Int J Oncol; 2017 Jul 05; 51(1):281-288. PubMed ID: 28535000 [Abstract] [Full Text] [Related]
10. How do we image patients with multiple myeloma and precursor states? Chakraborty R, Hillengass J, Lentzsch S. Br J Haematol; 2023 Nov 05; 203(4):536-545. PubMed ID: 37217164 [Abstract] [Full Text] [Related]
12. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C. Ann Hematol; 2019 Mar 05; 98(3):679-689. PubMed ID: 30539276 [Abstract] [Full Text] [Related]
13. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Park HY, Kim KW, Yoon MA, Lee MH, Chae EJ, Lee JH, Chung HW, Yoon DH. Cancer Imaging; 2020 Jan 30; 20(1):14. PubMed ID: 32000858 [Abstract] [Full Text] [Related]
14. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. AJR Am J Roentgenol; 2011 Sep 30; 197(3):W384-91. PubMed ID: 21862763 [Abstract] [Full Text] [Related]
15. The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT. Paternain A, García-Velloso MJ, Rosales JJ, Ezponda A, Soriano I, Elorz M, Rodríguez-Otero P, Aquerreta JD. Eur J Radiol; 2020 Dec 30; 133():109403. PubMed ID: 33202373 [Abstract] [Full Text] [Related]
16. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Balbo-Mussetto A, Cirillo S, Bruna R, Gueli A, Saviolo C, Petracchini M, Fornari A, Lario CV, Gottardi D, De Crescenzo A, Tarella C. Clin Radiol; 2016 Mar 30; 71(3):271-9. PubMed ID: 26749081 [Abstract] [Full Text] [Related]
17. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study. Spijkers S, Littooij AS, Kwee TC, Tolboom N, Beishuizen A, Bruin MCA, Elias SG, van de Brug T, Enríquez G, Sábado C, Miller E, Granata C, de Lange C, Verzegnassi F, Greer MC, de Keizer B, Nievelstein RAJ. Eur Radiol; 2021 Mar 30; 31(3):1494-1504. PubMed ID: 32880696 [Abstract] [Full Text] [Related]
18. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis. Rama S, Suh CH, Kim KW, Durieux JC, Ramaiya NH, Tirumani SH. AJR Am J Roentgenol; 2022 Apr 30; 218(4):602-613. PubMed ID: 34704461 [Abstract] [Full Text] [Related]
19. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP. J Nucl Med; 2014 Oct 30; 55(10):1598-604. PubMed ID: 25168627 [Abstract] [Full Text] [Related]
20. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A. Leuk Lymphoma; 2018 Nov 30; 59(11):2546-2556. PubMed ID: 29431555 [Abstract] [Full Text] [Related] Page: [Next] [New Search]